News
OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network’s OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL
First clinical trial to evaluate the safety and efficacy of …
2021-04-26
Poster Presentation at AACR 2021 Annual Meeting for OBI-3424, OBI-998, GLOBO H and SSEA-4
Title: Selective and Broad Anti-tumor Activity of AKR1C3-activated Prodrug AST-3424/OBI-3424 …
2021-04-11
OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4
Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 …
2021-04-06
OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference
Taipei, Taiwan. January 6, 2021 — OBI Pharma, Inc., a …
2021-01-06
ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine
1. Presentation number: 397P / Poster: ID 680 Title: A …
2020-11-23
OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine
Presentations to highlight the OBI-833 Phase 1 clinical study results …
2020-11-19
Company Announcement on Board Resolutions
Please refer to https://www.obipharma.com/2020/09/company-announcement-on-board-resolution/?lang=zh-hant for details.
2020-09-28
OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting
Presentation to highlight the scientific characteristics of the novel first-in-class …
2020-09-14
Poster Presentations at AACR 2020 Virtual Annual Meeting II
Session PO ET04.02 Identification of molecular targets 2 Title: The …
2020-06-22
OBI Pharma Announces Poster Presentations at AACR 2020 Virtual Annual Meeting II
Poster Presentations to highlight the role of the Globo H …
2020-06-16